Positive results using alternating electric field therapy in newly diagnosed glioblastoma

Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) is a novel treatment strategy for glioblastoma, delivered continuously by transducers applied to a shaved scalp. The TTFs is an antimitotic treatment that interferes with cell division and organelle assembly.

In an open-label randomized trial of 695 adults with newly diagnosed glioblastoma, median survival was improved in patients assigned to wear the device during the adjuvant temozolomide phase of standard chemo radiation compared with those assigned to standard chemo radiation alone (21 versus 16 months).  

Use of the device is encouraged in interested patients, although the requirement to carry a device and maintain a shaved scalp for the duration of the treatment presents a potential burden that it not acceptable to all patients. 

More about the randomized trial in the link

https://jamanetwork.com/journals/jama/fullarticle/2475463